Mefloquine and Dihydroartemisinin-piperaquine — Competitive Intelligence Brief

Mefloquine and Dihydroartemisinin-piperaquine (Mefloquine and Dihydroartemisinin-piperaquine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial combination. Area: Infectious Disease.

marketed Antimalarial combination Parasite heme polymerase (mefloquine); parasite proteins and lipids (dihydroartemisinin); hemozoin (piperaquine) Infectious Disease Small molecule

Target snapshot

Mefloquine and Dihydroartemisinin-piperaquine (Mefloquine and Dihydroartemisinin-piperaquine) — University of Oxford. This combination antimalarial works by disrupting parasite blood-stage development through multiple mechanisms: mefloquine inhibits heme polymerization in the parasite digestive vacuole, while dihydroartemisinin-piperaquine generates reactive oxygen species and inhibits parasite protein synthesis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Mefloquine and Dihydroartemisinin-piperaquine TARGET	Mefloquine and Dihydroartemisinin-piperaquine	University of Oxford	marketed	Antimalarial combination	Parasite heme polymerase (mefloquine); parasite proteins and lipids (dihydroartemisinin); hemozoin (piperaquine)
lumefantrine-artemether	lumefantrine-artemether	Centers for Disease Control and Prevention	marketed	Antimalarial combination	Malaria parasite (Plasmodium) hemoglobin metabolism and mitochondrial function
Pyronaridine artesunate	Pyronaridine artesunate	Medicines for Malaria Venture	marketed	Antimalarial combination	Plasmodium falciparum DNA; heme detoxification pathway
artesunate-amodiaquine (AS-AQ)	artesunate-amodiaquine (AS-AQ)	Yale University	marketed	Artemisinin derivative + aminoquinoline antimalarial combination	Plasmodium falciparum heme iron (Fe2+), parasite DNA, heme polymerase
artemether-lumefantrine (ALN)	artemether-lumefantrine (ALN)	Jhpiego	marketed	Antimalarial combination	Plasmodium falciparum heme metabolism and parasite membranes
artemisinin/naphthoquine	artemisinin/naphthoquine	Ifakara Health Institute	marketed	Antimalarial combination	Plasmodium falciparum heme metabolism and mitochondrial electron transport
lumefantrine plus artemether	lumefantrine plus artemether	Centers for Disease Control and Prevention	marketed	Antimalarial combination therapy	Malaria parasite heme metabolism and hemozoin formation

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial combination class)

1. Centers for Disease Control and Prevention · 4 drugs in this class
2. Armed Forces Research Institute of Medical Sciences, Thailand · 4 drugs in this class
3. London School of Hygiene and Tropical Medicine · 3 drugs in this class
4. Sanofi · 2 drugs in this class
5. Menzies School of Health Research · 2 drugs in this class
6. Fundação de Medicina Tropical Dr. Heitor Vieira Dourado · 1 drug in this class
7. Epicentre · 1 drug in this class
8. Jhpiego · 1 drug in this class
9. Charite University, Berlin, Germany · 1 drug in this class
10. Ifakara Health Institute · 1 drug in this class